A new research paper was published in Volume 16 of Oncotarget on July 9, 2025, titled "A novel anti-human CD25 mAb with ...

Song S et al. (2005) Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood 105: 1546–1548 ...

A new research paper was published in Volume 16 of Oncotarget on July 9, 2025, titled “A novel anti-human CD25 mAb with ...

To better understand the mechanisms behind this antibody-mediated protection, researchers closely examined one particularly effective antibody targeting a molecule called lipoarabinomannan (LAM ...

Astria Therapeutics' Navenibart shows promise in phase 3 trials for hereditary angioedema. Click here to find out why ATXS ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia . Clinical data showing unprecedented remission rates in newly diagnosed AML patient ...

Anselamimab is an anti-fibril monoclonal antibody designed to reduce or eliminate amyloid deposits by binding with targets of amino acids on misfolded amyloid fibrils.

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials. A ...

Explore the booming Myasthenia Gravis market in the 7MM with projections to 2034. Current therapies include prednisone and pyridostigmine, with monoclonal antibodies for aggressive cases. Valued at $6 ...

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.